

3. Benedict RHB, Comi G, Oreja-Guevara C, et al. Cognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data. Available from: <https://medically.roche.com/global/en/medical-material.c5dd6233-0990-4770-9208-35fcea91235.qr.html?cid=slprxx2210nexectrims2022>.
4. Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. *Lancet*. 2017;389(10076):1336-46.
5. Campbell J, Rashid W, Cercignani M, et al. Cognitive impairment among patients with multiple sclerosis: associations with employment and quality of life. *Postgrad Med J*. 2017;93(1097):143-147.
6. Castelo-Branco A, Landfeldt E, Svedbom A, et al. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study. *Eur J Neurol*. 2019;26(4):603-9.
7. Chen J, Taylor B, Palmer AJ, et al. Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. *Mult Scler*. 2019;25(7):994-1004.
8. Dorstyn DS, Roberts RM, Murphy G, et al. Employment and multiple sclerosis: a meta-analytic review of psychological correlates. *J Health Psychol*. 2019;24(1):38-51.
9. García-Domínguez JM, Maurino J, Martínez-Ginés ML, et al. Economic burden of multiple sclerosis in a population with low physical disability. *BMC Public Health*. 2019;19(1):609.
10. Glanz BI, Décano IR, Rintell DJ, et al. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. *Value Health*. 2012;15(8):1029-35.
11. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med*. 2017;376(3):221-34.
12. Johnson KL, Yorkston KM, Klasner ER, et al. The cost and benefits of employment: a qualitative study of experiences of persons with multiple sclerosis. *Arch Phys Med Rehabil*. 2004;85(2):201-9.
13. Julian LJ, Vella L, Vollmer T, et al. Employment in multiple sclerosis: Exiting and re-entering the work force. *J Neurol*. 2008;255(9):1354-60.
14. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. *JAMA Neurol*. 2020;77(9):1132-1140.
15. Landfeldt E, Castelo-Branco A, Svedbom A, et al. Sick leave and disability pension before and after diagnosis of multiple sclerosis. *Mult Scler*. 2016;22(14):1859-66.
16. Lehmann AI, Rodgers S, Kamm CP, et al. Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study. *J Neurol*. 2020;267:3069-3082.
17. Marck CH, Aitken Z, Simpson S Jr, et al. Predictors of change in employment status and associations with quality of life: a prospective international study of people with multiple sclerosis. *J Occup Rehabil*. 2020;30(1):105-14.
18. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med*. 2017;376(3):209-20.
19. Nicholas JA, Electricwala B, Lee LK, et al. Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data. *BMC Neurol*. 2019;19(1):258.
20. Povolio CA, Blair M, Mehta S, Rosehart H, et al. Predictors of vocational status among persons with multiple sclerosis. *Mult Scler Relat Disord*. 2019; 36:101411.
21. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. *N Engl J Med*. 2018;378(2):169-80.
22. Reilly Associates. WPAL: SHP V2. 0. Available from: http://www.reillyassociates.net/wpai_shp.html.
23. Rumrill P, Li J, Strauser D, et al. Personal, health and function, and career maintenance factors as determinants of quality of life among employed people with multiple sclerosis. *Work*. 2020;67(1):81-94.
24. Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. *J Neurol*. 2010;257(6):926-36.
25. Strober L, DeLuca J, Benedict RH, et al. Symbol Digit Modalities Test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. *Mult Scler*. 2019;25(13):1781-1790.
26. Strober LB, Bruce JM, Arnett PA, et al. A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT). *Mult Scler Relat Disord*. 2022;57:103405.
27. van Gorp DAM, van der Hiele K, Heerings MAP, et al. Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. *Neurol Sci*. 2019;40(12):2555-2564.
28. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. *Mult Scler J*. 2020;16(14):1816-21.
29. Weindel H, Benedict RHB, Comi G, et al. Employment and Cognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data. Dostupné na: <https://medically.roche.com/global/en/medical-material.6327f9d0-1652-4bcc-b945-9dbefad807dd.qr.html?cid=slprxx2210nexectrims2022>.
30. Weinstock Z, Morrow S, Conway D, et al. Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. *Mult Scler*. 2022;28(7):1101-1111.

ON-LINE KURZ

On-line kurz pro praktické neurology

Trendy v léčbě migrény

3

2022

PŘEDNÁŠKY

- Význam studie PEARL pro klinickou praxi – MUDr. Jolana Marková, FEAN
- Medication overuse headache a role anti-CGRP – MUDr. Petra Migalová
- Lékové interakce migréna a RS – update – PharmDr. Josef Suchopár
- Výhody flexibility podání fremanezumabu u našich pacientů – MUDr. Monika Záhumenská

ODBORNÝ GARANT

MUDr. Jolana Marková, FEAN
Neurologická klinika, Fakultní Thomayerova nemocnice v Praze

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN

prosinec 2022
až listopad 2023
dostupný na
online.solen.cz

PARTNER


